Bristol-Myers Squibb Company
NYSE: BMY
$54.14
-$0.57 (-1.0%)
Closing Price on November 8, 2024
BMY Articles
These five Goldman Sachs high-conviction stock picks look like outstanding total return ideas now. They are positioned well for the rest of 2021 and beyond, and they make sense for growth and income...
Published:
Friday's top analyst upgrades and downgrades included AvalonBay Communities, Bristol-Myers Squibb, Carrier, Comcast, CyrusOne, DraftKings, Nvidia and Textron.
Published:
Tuesday's top analyst upgrades and downgrades included Beyond Meat, Booking, Bristol-Myers Squibb, Cloudflare, FedEx, JetBlue Airways, Nvidia, PepsiCo, Square and Zscaler.
Published:
These five top picks from the Goldman Sachs America's Conviction List look poised for great total return potential and less potential volatility in a very overbought stock market. They all pay...
Published:
The analysts at BofA Securities have added an IT services giant to the firm's US 1 List of top stock recommendations. Plus, here are three additional ideas that make sense for growth investors now
Published:
BofA Securities says that, given current market conditions, it makes sense for investors to move to safer stocks that pay dividends. These five look like great places to park some portfolio money now...
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
With the market bloated and way overbought, what many feel makes sense for 2021 are dividend-paying stocks with solid growth potential that can deliver solid total return. These five top stocks on...
Published:
In a move that investors looking for more defensive ideas should applaud, the analysts at Goldman Sachs have added Bristol-Myers Squibb to the Americas Conviction List. Plus, here are four additional...
Published:
Tuesday's top analyst upgrades and downgrades included Baker Hughes, Bristol Meyers, Chevron, Emerson, Halliburton, HCA, Intuitive Surgical, Medtronic, NXP Semiconductors and Phillips 66.
Published:
These five dividend-paying stocks have solid growth potential and can deliver solid total return. The companies have very strong and defensible business models and products. So their stocks make...
Published:
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
Published:
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Published:
Monday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Chewy, DraftKings, Exxon Mobil, McAfee, Nvidia, Square, Tilray and Walt Disney.
Published:
Pharmaceuticals giant Bristol-Myers reported third-quarter results Thursday morning that beat analysts' expectations on both the top and bottom lines. So why did shares trade lower?
Published: